Brain-Derived Neurotrophic Factor in Pediatric Acquired Brain Injury and Recovery

Area of Science:

• Neuroscience
• Biomarkers
• Pediatric Neurology

Background:

• Pediatric acquired brain injury (ABI) encompasses traumatic brain injury, global cerebral ischemia, and stroke.
• Accurate prognostic tools and treatment monitoring are crucial for managing pediatric ABI.
• Brain-derived neurotrophic factor (BDNF) is a key molecule in neural development and plasticity.

Purpose of the Study:

• To review evidence on BDNF protein, genotype, and DNA methylation as biomarkers for pediatric ABI outcomes.
• To explore BDNF's role in environmental influences, rehabilitation response, and modifiability.
• To highlight BDNF's potential to improve prognostic accuracy and guide clinical decisions in pediatric ABI.

Main Methods:

• Review of preclinical and clinical evidence.
• Analysis of BDNF as a biomarker across different pediatric ABI etiologies.
• Synthesis of data on BDNF's interaction with the environment and therapeutic interventions.

Main Results:

• Emerging evidence supports BDNF (protein, genotype, DNA methylation) as a biomarker for pediatric ABI.
• BDNF is implicated in embedding psychosocial influences and is responsive to rehabilitative therapies.
• BDNF is potentially modifiable, offering therapeutic targets.

Conclusions:

• BDNF serves as a unique biomarker of neuroplasticity and neural repair in pediatric ABI.
• It reflects pre- and post-injury environmental factors, distinguishing it from structural biomarkers.
• BDNF has significant potential to enhance pediatric ABI management through improved prognostication and treatment monitoring.